Stelios Papadopoulos, Ph.D. (chairman) Michael M. Morrissey, Ph.D. (president & CEO)[1]
Revenue
US$ 1.435 Billion (2021)[2]
Operating income
US$ 0.287 Billion (2021)[3]
Net income
US$ 0.231 Billion (2021)[4]
Total assets
US$ 2.61 Billion (2021)[5]
Total equity
US$ 2.211 Billion (2021)[6]
Number of employees
954 (2021)[7]
Website
exelixis.com
Footnotes / references [8]
Exelixis, Inc. is a genomics-based drug discovery company located in Alameda, California, and the producer of Cometriq, a treatment approved by the U.S. Food and Drug Administration (FDA) for medullary thyroid cancer with clinical activity in several other types of metastatic cancer.
^"Exelixis Inc. Profile". MarketWatch.com. Retrieved January 6, 2020.
^"Exelixis Revenue 2010-2022".
^"Exelixis Operating Income 2010-2022".
^"Exelixis Net Income 2010-2022".
^"Exelixis Total Assets 2010-2022".
^"Exelixis Share Holder Equity 2010-2022".
^"Exelixis: Number of Employees 2010-2022".
^"US SEC: Form 10-K Exelixis, Inc". U.S. Securities and Exchange Commission. Retrieved November 3, 2021.
"Exelixis Revenue 2010-2022". "Exelixis Operating Income 2010-2022". "Exelixis Net Income 2010-2022". "Exelixis Total Assets 2010-2022". "Exelixis Share...
VEGFR2, and also inhibits AXL and RET. It was discovered and developed by Exelixis Inc. In November 2012, cabozantinib in its capsule formulation was approved...
Harvard Crimson. Retrieved June 10, 2019. "Exelixis Appoints Dr. Alan M. Garber to Board of Directors". Exelixis, Inc. Retrieved December 4, 2019. "Vertex...
experimental drug candidate for the treatment of cancer. It was discovered by Exelixis and is under development by GlaxoSmithKline. About 10 Phase II clinical...
Clinical Trials Program (Exelixis). Official US HCP Website. Retrieved 2024-01-09. "Stellar 303". STELLAR Clinical Trials Program (Exelixis). Official US HCP...
Eversource ES Utilities Multi-Utilities Exact Sciences EXAS Health Care Exelixis EXEL Health Care Biotechnology Exelon EXC Utilities Multi-Utilities Expedia...
previously the chief executive officer of Biogen from 2010 to 2016 and of Exelixis from 1996 to 2010. Prior to joining industry, Scangos was a professor of...
children aged two years and older. In 2016, Ipsen licensed cabozantinib from Exelixis, which received marketing authorization the same year for the second-line...
cancer and polycystic kidney disease. The drug was first developed by Exelixis, Inc. and was later acquired by Kadmon Corporation. Tesevatinib binds to...
XL-550) is a nonsteroidal antimineralocorticoid which was discovered by Exelixis and developed by Daiichi Sankyo Company and is approved in Japan for the...
BayStateHealth.org. April 18, 2017. the Non-Clinical Collaboration Award "Exelixis Enters into a Clinical Collaboration for Three Phase 3 Combination Trials...
maint: archived copy as title (link) "Board of Directors". "Exelixis' Board of Directors". Exelixis. Meet our team are.com Van Zandt, Emily. "Meet our 2017...
from the original on 2022-01-11. Retrieved 2012-12-17. "Cobimetinib at exelixis.com". Archived from the original on 2015-02-04. Retrieved 2015-02-04. "MEK/BRAF...
taribavirin (now KD024). Cancer drugs XL647 and XL844 were acquired from Exelixis. An inhibitor of several protein kinases, tesevatinib (XL647, KD019) entered...
participated in the First Open Dialogue “Act for the Future”, organized by EXELIXI ZOIS and held at Stavros Niarchos Foundation, and in April 2023, the company...
by Oxford included Martek Biosciences Corporation, Geron Corporation, Exelixis, and Gene Finder, among others. In 1992, Walton, Wally Steinberg, and Craig...
Global Information
US$ 1.435 Billion (2021)[2]